Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms.
Study Goal
The researchers aimed to summarize the impact of melatonin on Parkinson's disease (PD) by reviewing preclinical and clinical studies, focusing on its effects on molecular mechanisms and clinical symptoms.
Results Summary
Melatonin supplementation was found to inhibit pathways related to apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and dopamine loss in PD. It also improved some nonmotor symptoms in PD patients, though limited studies have evaluated its role in molecular mechanisms and clinical symptoms.
Population
Patients with Parkinson's disease (PD) and preclinical models.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin supplementation | neutral | PD | preclinical and clinical studies | - | is an appropriate therapy | #1 |
melatonin | decrease | apoptosis | PD | - | leads to inhibition | #2 |
melatonin | decrease | autophagy | PD | - | leads to inhibition | #3 |
melatonin | decrease | oxidative stress | PD | - | leads to inhibition | #4 |
melatonin | decrease | inflammation | PD | - | leads to inhibition | #5 |
melatonin | decrease | α-synuclein aggregation | PD | - | leads to inhibition | #6 |
melatonin | decrease | dopamine loss | PD | - | leads to inhibition | #7 |
melatonin | increase | some nonmotor symptom | patients with PD | - | improves | #8 |
Parkinson disease (PD) is a chronic and neurodegenerative disease with motor and nonmotor symptoms. Multiple pathways are involved in the pathophysiology of PD, including apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and changes in the neurotransmitters. Preclinical and clinical studies have shown that melatonin supplementation is an appropriate therapy for PD. Administration of melatonin leads to inhibition of some pathways related to apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and dopamine loss in PD. In addition, melatonin improves some nonmotor symptom in patients with PD. Limited studies, however, have evaluated the role of melatonin on molecular mechanisms and clinical symptoms in PD. This review summarizes what is known regarding the impact of melatonin on PD in preclinical and clinical studies.